2 Information about axicabtagene ciloleucel

Marketing authorisation indication

2.1 Axicabtagene ciloleucel (Yescarta, Kite) is indicated for 'the treatment of adult patients with r/r [relapsed or refractory] follicular lymphoma (FL) after three or more lines of systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for axicabtagene ciloleucel.


2.3 The list price of axicabtagene ciloleucel for a single infusion including shipping, engineering and generation of chimeric antigen receptor (CAR) T cells is £280,451 (company submission). The company has a commercial arrangement. This makes axicabtagene ciloleucel available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)